← Russell 3000 cross-section

PDEX PRO DEX INC

Trailing twelve months to 2026-03-31 · as filed 2026-04-30, not restated
Healthcare

Scale

Market cap
$207m
Revenue TTM
$75m
Net income TTM
$12m
Free cash flow
Composite score
Sector rank
#2855

Valuation

P / E
17.2
EV / EBITDA
16.5
EV / sales
2.7
FCF yield
Earnings yield vs 10-yr
1.07pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
16.1%
EBITDA margin
16.2%
ROE
26.6%
ROIC
28.8%
Revenue growth
16.4%

Insider activity, last 90 days

Net open-market
$-0.05m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Business Strategy and Future Plans Our business today is almost entirely driven by sales of our medical devices. During the third quarter of fiscal 2026, we completed the acquisition of APM, one of our significant suppliers, to help meet the increased demand as a result of this contract extension. Details of our medical device sales by type is as follows (in thousands, except percentages): Sales of our medical device products increased $4.3 million, or 36%, and $11.7 million, or 35%, respectively, for the three and nine months ended March 31, 2026, compared to the corresponding periods of the prior fiscal year. …PRO DEX INC, 10-Q, period ended 2026-03-31, filed 2026-04-30

Read the full passage →